180 related articles for article (PubMed ID: 33723362)
1. Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study.
Palumbo C; Antonelli A; Triggiani L; Dalla Volta A; Maffezzoni F; Zamboni S; Borghetti P; Rinaudo L; Valcamonico F; Maroldi R; Magrini SM; Simeone C; Berruti A;
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):852-859. PubMed ID: 33723362
[TBL] [Abstract][Full Text] [Related]
2. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
Elife; 2024 Apr; 13():. PubMed ID: 38656229
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity in regional changes in body composition induced by androgen deprivation therapy in prostate cancer patients: potential impact on bone health-the BLADE study.
Dalla Volta A; Palumbo C; Zamboni S; Mazziotti G; Triggiani L; Zamparini M; Maffezzoni F; Rinaudo L; Bergamini M; Di Meo N; Caramella I; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Berruti A
J Endocrinol Invest; 2024 Feb; 47(2):335-343. PubMed ID: 37458931
[TBL] [Abstract][Full Text] [Related]
4. Effect of Degarelix Administration on Bone Health in Prostate Cancer Patients Without Bone Metastases. The Blade Study.
Palumbo C; Dalla Volta A; Zamboni S; Mazziotti G; Zamparini M; Triggiani L; Borghetti P; Maffezzoni F; Bresciani R; Rinaudo L; Valcamonico F; Farina D; Magrini SM; Antonelli A; Simeone C; Berruti A
J Clin Endocrinol Metab; 2022 Nov; 107(12):3398-3407. PubMed ID: 35971857
[TBL] [Abstract][Full Text] [Related]
5. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
Inoue T; Mizowaki T; Kabata D; Shintani A; Terada N; Yamasaki T; Negoro H; Kobayashi T; Nakamura K; Inokuchi H; Ogawa O
Clin Genitourin Cancer; 2018 Apr; 16(2):135-141.e1. PubMed ID: 29051056
[TBL] [Abstract][Full Text] [Related]
6. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer.
Boxer RS; Kenny AM; Dowsett R; Taxel P
Aging Male; 2005; 8(3-4):207-12. PubMed ID: 16390748
[TBL] [Abstract][Full Text] [Related]
7. Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study.
Sawazaki H; Araki D; Kitamura Y; Yagi K
World J Urol; 2020 Jun; 38(6):1465-1471. PubMed ID: 31482294
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer.
Klotz L
Expert Opin Drug Metab Toxicol; 2015; 11(11):1795-802. PubMed ID: 26513436
[TBL] [Abstract][Full Text] [Related]
9. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
10. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
11. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
Sayyid RK; Evans A; Hersey K; Maloni R; Hurtado-Coll A; Kulkarni G; Finelli A; Zlotta AR; Hamilton R; Gleave M; Fleshner NE
Clin Cancer Res; 2017 Apr; 23(8):1974-1980. PubMed ID: 27756786
[No Abstract] [Full Text] [Related]
12. Does Exist a Differential Impact of Degarelix
Sciarra A; Busetto GM; Salciccia S; Del Giudice F; Maggi M; Crocetto F; Ferro M; De Berardinis E; Scarpa RM; Porpiglia F; Carmignani L; Damiano R; Artibani W; Carrieri G
Front Endocrinol (Lausanne); 2021; 12():695170. PubMed ID: 34194398
[TBL] [Abstract][Full Text] [Related]
13. FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.
Crawford ED; Tombal B; Keane T; Boccardo F; Miller K; Shore N; Moul JW; Damber JE; Collette L; Persson BE
Scand J Urol; 2018; 52(5-6):349-357. PubMed ID: 30624128
[TBL] [Abstract][Full Text] [Related]
14. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
[TBL] [Abstract][Full Text] [Related]
15. Optimizing subcutaneous injection of the gonadotropin-releasing hormone receptor antagonist degarelix.
Barkin J; Burton S; Lambert C
Can J Urol; 2016 Feb; 23(1):8179-83. PubMed ID: 26892063
[TBL] [Abstract][Full Text] [Related]
16. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
17. Utility of LHRH antagonists for advanced prostate cancer.
Moul JW
Can J Urol; 2014 Apr; 21(2 Supp 1):22-7. PubMed ID: 24775720
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
de la Rosette J; Davis R; Frankel D; Kold Olesen T
Int J Clin Pract; 2011 May; 65(5):559-66. PubMed ID: 21342376
[TBL] [Abstract][Full Text] [Related]
19. A review of clinical evidence to assess differences in efficacy and safety of luteinizing hormone-releasing hormone (LHRH) agonist (goserelin) and LHRH antagonist (degarelix).
Bahl A; Rajappa S; Rawal S; Bakshi G; Murthy V; Patil K
Indian J Cancer; 2022 Mar; 59(Supplement):S160-S174. PubMed ID: 35343199
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
